{"entity":{"id":"nct02767804","kind":"trial","name":"eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients","aka":[],"tldr":"A phase 3 trial of Ensartinib, Crizotinib in non-small-cell lung cancer and small-cell lung cancer, run by Xcovery Holdings, Inc., active and no longer recruiting.","summary":"eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients is a phase 3 interventional study registered as NCT02767804 by Xcovery Holdings, Inc., with 290 participants enrolled, started 2016-06 and due to reach its primary completion in 2025-12-30. Interventions recorded: X-396 (ensartinib), crizotinib. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT02767804","url":"https://clinicaltrials.gov/study/NCT02767804"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["ensartinib","crizotinib"],"companies":["xcovery"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT02767804","phase":"3","setting":"Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients","sponsor":"Xcovery Holdings, Inc.","enrolled":290,"outcomes":[]},"route":"/trials/nct02767804/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"crizotinib","kind":"drug","name":"Crizotinib","route":"/drugs/crizotinib/"},{"id":"ensartinib","kind":"drug","name":"Ensartinib","route":"/drugs/ensartinib/"}],"company":[{"id":"xcovery","kind":"company","name":"Xcovery","route":"/companies/xcovery/"}]}}